Literature DB >> 6821869

Mechanisms of abnormal erythropoiesis in malignancy.

N Dainiak, V Kulkarni, D Howard, M Kalmanti, M C Dewey, R Hoffman.   

Abstract

In order the investigate mechanisms of diminished red cell production in malignancy, we assayed erythroid progenitor cell proliferative responses to erythropoietin in plasma clot cultures of bone marrow cells from 34 cancer patients. Erythroid colony growth by marrow cells of 11 healthy donors (means of 58 CFU-E and 19 BFU-E derived colonies/6 X 10(4) cells) was similar to that in cultures of cells from patients either with (means of 44 CFU-E and 22 BFU-E derived colonies/6 X 10(4) cells) or without (means of 50 CFU-E and 19 BFU-E derived colonies/6 X 10(4) cells) myelophthisis. Colony formation was normal at all erythropoietin concentrations tested, indicating that both the CFU-E and BFU-E retain normal erythropoietin sensitivity in vitro. CFU-E proliferation correlated negatively (r = -0.56; P less than 0.001) with the level of hemoglobin. In contrast to marrow cell proliferative responses to erythropoietin, serum erythropoietin levels were inappropriately reduced in all 19 patients in whom they were measured, a finding which may be important in the pathogenesis of anemia in patients with cancer.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6821869     DOI: 10.1002/1097-0142(19830315)51:6<1101::aid-cncr2820510622>3.0.co;2-g

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  2 in total

1.  Effects of chemotherapeutic and immunosuppressive drugs on the production of erythropoietin in human hepatoma cultures.

Authors:  M Wolff; W Jelkmann
Journal:  Ann Hematol       Date:  1993-01       Impact factor: 3.673

2.  The effect of recombinant human erythropoietin treatment on tumour radiosensitivity and cancer-associated anaemia in the mouse.

Authors:  B Joiner; V K Hirst; S R McKeown; J J McAleer; D G Hirst
Journal:  Br J Cancer       Date:  1993-10       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.